Suzhou Ribo Life Science Co., Ltd. (HKG:6938)
Hong Kong · Delayed Price · Currency is HKD 51.50
+2.50 (5.10%)
Aug 20, 2026, 4:09 PM HKT
Suzhou Ribo Life Science Revenue
In the year 2025, Suzhou Ribo Life Science had annual revenue of 148.51M CNY with 4.12% growth. Suzhou Ribo Life Science had revenue of 44.70M in the half year ending December 31, 2025.
Revenue
148.51M CNY
Revenue Growth
+4.12%
P/S Ratio
53.15
Revenue / Employee
364.89K CNY
Employees
407
Market Cap
8.78B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 148.51M | 5.88M | 4.12% |
| Dec 31, 2024 | 142.63M | 142.58M | 324,052.27% |
| Dec 31, 2023 | 44.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Everest Medicines | 2.78B |
| Shanghai Haohai Biological Technology | 2.73B |
| Lepu Biopharma | 1.14B |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |
| CARsgen Therapeutics Holdings | 157.72M |
| Ascletis Pharma | 2.26M |
Suzhou Ribo Life Science News
- 5 months ago - Suzhou Ribo Life Science Earnings release: H2 2025 - Filings
- 5 months ago - Suzhou Ribo Life Science Annual report: H2 2025 - Filings